Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Payables (2016 - 2025)

Historic Payables for Anaptysbio (ANAB) over the last 11 years, with Q3 2025 value amounting to $2.9 million.

  • Anaptysbio's Payables fell 1945.99% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 1945.99%. This contributed to the annual value of $4.0 million for FY2024, which is 1481.48% down from last year.
  • According to the latest figures from Q3 2025, Anaptysbio's Payables is $2.9 million, which was down 1945.99% from $3.3 million recorded in Q2 2025.
  • Anaptysbio's Payables' 5-year high stood at $6.5 million during Q3 2023, with a 5-year trough of $1.6 million in Q2 2022.
  • Moreover, its 5-year median value for Payables was $3.6 million (2024), whereas its average is $3.8 million.
  • As far as peak fluctuations go, Anaptysbio's Payables crashed by 7139.19% in 2021, and later soared by 20000.0% in 2023.
  • Anaptysbio's Payables (Quarter) stood at $1.7 million in 2021, then surged by 59.91% to $2.8 million in 2022, then surged by 68.75% to $4.7 million in 2023, then dropped by 14.81% to $4.0 million in 2024, then dropped by 27.71% to $2.9 million in 2025.
  • Its Payables stands at $2.9 million for Q3 2025, versus $3.3 million for Q2 2025 and $6.1 million for Q1 2025.